THERAPY Risk of metformin use in patients with T2DM and advanced CKD

被引：9
|
作者：
Schernthaner, Guntram [1 ]
Schernthaner-Reiter, Marie Helene [2 ]
机构：
[1] Rudolfstiftung Hosp, Dept Med 1, A-1030 Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 3, Clin Div Endocrinol & Metab, A-1090 Vienna, Austria
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2015年 / 11卷 / 12期
关键词：
KIDNEY-DISEASE; MORTALITY;
D O I：
10.1038/nrendo.2015.132
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.
引用
收藏
页码：697 / 698
页数：2
相关论文
共 50 条
  • [1] Risk of metformin use in patients with T2DM and advanced CKD
    Guntram Schernthaner
    Marie Helene Schernthaner-Reiter
    [J]. Nature Reviews Endocrinology, 2015, 11 : 697 - 699
  • [2] Risk Factors for Incident T2DM in Patients with Prediabetes by CKD Status
    Hennessey, Kelly A.
    Alicic, Radica Z.
    Daratha, Kenn B.
    Jones, Cami
    Neumiller, Joshua J.
    Duru, O. Kenrik
    Nicholas, Susanne
    McPherson, Sterling M.
    Norris, Keith C.
    Tuttle, Katherine R.
    [J]. DIABETES, 2020, 69
  • [3] Metformin safety in T2DM patients with psoriasis
    [J]. Reactions Weekly, 2019, 1743 (1) : 10 - 10
  • [4] T2DM/CKD genetic risk scores and the progression of diabetic kidney disease in T2DM subjects
    Galuska, David
    Pacal, Lukas
    Chalasova, Katarina
    Divacka, Petra
    Rehorova, Jitka
    Svojanovsky, Jan
    Hubacek, Jaroslav A.
    Lanska, Vera
    Kankova, Katerina
    [J]. GENE, 2024, 927
  • [5] Renoprotective effects of dulaglutide in patients with T2DM and CKD
    Sorensen, Charlotte M.
    Holst, Jens J.
    [J]. NATURE REVIEWS NEPHROLOGY, 2018, 14 (11) : 659 - 660
  • [6] Renoprotective effects of dulaglutide in patients with T2DM and CKD
    Charlotte M. Sorensen
    Jens J. Holst
    [J]. Nature Reviews Nephrology, 2018, 14 : 659 - 660
  • [7] THE RISK OF COBALAMIN DEFICIENCY SYMPTOMS RELATED TO LONG-TERM METFORMIN USE IN T2DM PATIENTS
    Hendrawati, Y. D.
    Andrajati, R.
    Supardi, S.
    Ariyani, A.
    [J]. ACTA ENDOCRINOLOGICA-BUCHAREST, 2018, 14 (01) : 49 - 54
  • [8] CV benefits of finerenone in T2DM and CKD
    Huynh K.
    [J]. Nature Reviews Cardiology, 2021, 18 (11) : 738 - 738
  • [9] Risk of cardiovascular disease in patients with T2DM
    [J]. Nature Reviews Endocrinology, 2013, 9 (6) : 316 - 316
  • [10] Insulin plus metformin for T2DM—are there benefits?
    Clifford J. Bailey
    [J]. Nature Reviews Endocrinology, 2012, 8 : 449 - 450
12345